Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - triamcinolone acetonide 0.05%{relative};  ;   - topical cream - 0.05 % - active: triamcinolone acetonide 0.05%{relative}     excipient: benzyl alcohol emulsifying wax glycerol isopropyl palmitate lactic acid purified water sodium hydroxide sorbitol as 70% solution

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - triamcinolone acetonide 0.02% - topical ointment - 0.02% w/w - active: triamcinolone acetonide 0.02% excipient: white soft paraffin - in the treatment of the following dermatoses; atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, eczematised psoriasis, neurodermatitis.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - triamcinolone acetonide 0.05%;  ;   - topical ointment - 0.05 % - active: triamcinolone acetonide 0.05%     excipient: white soft paraffin

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin - capsule - 150 mg - active: clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin excipient: erythrosine gelatin indigo carmine lactose monohydrate magnesium stearate maize starch opacode white s-1-18086 purified talc titanium dioxide - upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever. lower respiratory infections including bronchitis, pneumonia, empyema and lung abscess.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency.;  ;  ; clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency. - capsule - 150 mg - active: clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency.     excipient: erythrosine gelatin indigo carmine ink lactose monohydrate magnesium stearate maize starch purified talc titanium dioxide active: clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency. excipient: gelatin ink lactose monohydrate magnesium stearate maize starch purified talc titanium dioxide - clindamycin hydrochloride has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever. 2.lower respiratory infections including bronchitis, pneumonia, emphysema and lung abscess. 3. skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses, and wound infections. for specific skin and soft tissue infections like erysipelas and paronychia (panaritium), it would seem logical that these conditions would respond very well to clindamycin therapy. 4. bone and joint infections including osteomyelitis and septic arthritis. 5. pelvic infections including endometritis, cellulitis, vaginal cuff infection tubo-ovarian abscesses salpingitis and pelvic inflammatory disease when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. in cases of cervicitis due to chlamydia trachomatis, mono therapy with clindamycin has been shown to be effective in eradicating the organism. 6. intra-abdominal infections including peritonitis and abdominal abscess when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. 7. septicemia and endocarditis - the effectiveness of clindamycin in the treatment of selected cases of endocarditis has been documented when clindamycin is determined to be bactericidal to the infecting organism by in vitro testing of appropriate achievable serum concentrations. 8. dental infections such as periodental abscess and periodonitis. 9. as an alternative therapy when used in combination with quinine or amodiaquine for the treatment of multi-drug resistant plasmodium falciporum infection.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml;  ;  ;   - solution for injection - 600mg/4ml - active: clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml       excipient: benzyl alcohol disodium edetate dihydrate hydrochloric acid sodium hydroxide water for injection - clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - clindamycin hydrochloride 162.87mg equivalent to clindamycin 150 mg;  ;   - capsule - 150 mg - active: clindamycin hydrochloride 162.87mg equivalent to clindamycin 150 mg     excipient: gelatin lactose monohydrate magnesium stearate maize starch opacode black s-1-277002 purified talc titanium dioxide - clindamycin hydrochloride has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: · upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever. · lower respiratory infections including bronchitis, pneumonia, emphysema and lung abscess. · skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses, and wound infections. for specific skin and soft tissue infections like erysipelas and paronychia (panaritium), it would seem logical that these conditions would respond very well to clindamycin therapy. · bone and joint infections including osteomyelitis and septic arthritis. · pelvic infections including endometritis, cellulitis, vaginal cuff infection tubo-ovarian abscesses salpingitis and pelvic inflammatory disease when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. in cases of cervicitis due to chlamydia trachomatis, mono therapy with clindamycin has been shown to be effective in eradicating the organism. · intra-abdominal infections including peritonitis and abdominal abscess when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. · septicemia and endocarditis - the effectiveness of clindamycin in the treatment of selected cases of endocarditis has been documented when clindamycin is determined to be bactericidal to the infecting organism by in vitro testing of appropriate achievable serum concentrations. · dental infections such as periodontal abscess and periodontitis. · as an alternative therapy when used in combination with quinine or amodiaquine for the treatment of multi-drug resistant plasmodium falciparum infection.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - azithromycin dihydrate 524.1mg equivalent to 500 mg azithromycin - powder for infusion - 500 mg - active: azithromycin dihydrate 524.1mg equivalent to 500 mg azithromycin excipient: citric acid sodium hydroxide - the treatment of community acquired pneumonia (cap) caused by susceptible organisms, including legionella pneumophila, in patients who require initial intravenous therapy.

Israel - englanti - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - hydrocortisone as sodium succinate - powder for solution for inj/inf - hydrocortisone as sodium succinate 500 mg/vial - hydrocortisone - hydrocortisone - solu-cortef is indicated to treat any condition in which im or iv corticosteroid treatment is required such as: - allergic states, - dermatologic diseases, - endocrine disorders, - gastrointestinal diseases,- hematologic disorders, - neoplastic diseases, - nervous system disorders, - ophthalmic diseases, - renal diseases, - respiratory diseases, - rheumatic disorders,- certain medical emergencies.

Israel - englanti - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - hydrocortisone as sodium succinate - powder for solution for inj/inf - hydrocortisone as sodium succinate 100 mg - hydrocortisone - hydrocortisone - solu-cortef is indicated to treat any condition in which im or iv corticosteroid treatment is required such as: - allergic states, - dermatologic diseases, - endocrine disorders, - gastrointestinal diseases,- hematologic disorders, - neoplastic diseases, - nervous system disorders, - ophthalmic diseases, - renal diseases, - respiratory diseases, - rheumatic disorders,- certain medical emergencies.